5514. Liraglutide

Nomenclature

CAS number: 204656-20-2
l-Histidyl-l-alanyl-l-α-glutamylglycyl-l-threonyl-l-phenylalanyl-l-threonyl-l-seryl-l-α-aspartyl-l-valyl-l-seryl-l-seryl-l-tyrosyl-l-leucyl-l-α-glutamylglycyl-l-glutaminyl-l-alanyl-l-alanyl-N6-[N-(1-oxohexadecyl)--l-γ-glutamyl]-l-lysyl-l-α-glutamyl-l-phenylalanyl-l-isoleucyl-l-alanyl-l-tryptophyl-l-leucyl-l-valyl-l-arginylglycyl-l-arginylglycine; N26-(Hexadecanoyl-γ-glutamyl)-(34-arginine)GLP-1-(7-37)-peptide; Lys26(Nε-(γ-glutamyl-(Nα-hexadecanoyl))), Arg34-GLP-1(7-37); NN-2211.
C172H265N43O51; mol wt 3751.20.
C 55.07%, H 7.12%, N 16.06%, O 21.75%.

Description and references

Acylated derivative of glucagon-like peptide 1, q.v. Prepn: L. B. Knudsen et al., WO 9808871; idem et al., US 6268343 (1998, 2001 both to Novo Nordisk); eidem, J. Med. Chem. 43, 1664 (2000). Clinical effect on glucose and insulin homeostasis: H. Agerso, P. Vicini, Eur. J. Pharm. Sci. 19, 141 (2003). Clinical pharmacokinetics: B. Elbrond et al., Diabetes Care 25, 1398 (2002). Clinical trial in type 2 diabetes: S. Madsbad et al., ibid. 27, 1335 (2004); M. N. Feinglos et al., Diabet. Med. 22, 1016 (2005). Review of mechanism of action and efficacy: T. Vilsboll, Expert Opin. Invest. Drugs 16, 231-237 (2007).

Chemical structure

Therapeutic Category

Antidiabetic.

Keywords

Antidiabetic; Hormones/Analogs